AU2001255168A1 - Compositions and methods for the treatment of immune related diseases - Google Patents
Compositions and methods for the treatment of immune related diseasesInfo
- Publication number
- AU2001255168A1 AU2001255168A1 AU2001255168A AU5516801A AU2001255168A1 AU 2001255168 A1 AU2001255168 A1 AU 2001255168A1 AU 2001255168 A AU2001255168 A AU 2001255168A AU 5516801 A AU5516801 A AU 5516801A AU 2001255168 A1 AU2001255168 A1 AU 2001255168A1
- Authority
- AU
- Australia
- Prior art keywords
- compositions
- treatment
- methods
- related diseases
- immune related
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18720200P | 2000-03-03 | 2000-03-03 | |
| US60/187,202 | 2000-03-03 | ||
| US19101500P | 2000-03-21 | 2000-03-21 | |
| US60/191,015 | 2000-03-21 | ||
| AU55911/00 | 2000-05-30 | ||
| PCT/US2000/014941 WO2000073348A2 (en) | 1999-06-02 | 2000-05-30 | Methods and compositions for inhibiting neoplastic cell growth |
| US20983200P | 2000-06-05 | 2000-06-05 | |
| US60/209,832 | 2000-06-05 | ||
| AU75730/00 | 2000-08-24 | ||
| PCT/US2000/023328 WO2001016318A2 (en) | 1999-09-01 | 2000-08-24 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US60/000,000 | 2000-09-15 | ||
| AU20554/01 | 2000-12-01 | ||
| PCT/US2000/032678 WO2001040466A2 (en) | 1999-12-01 | 2000-12-01 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| PCT/US2001/006666 WO2001066740A2 (en) | 2000-03-03 | 2001-03-01 | Compositions and methods for the treatment of immune related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001255168A1 true AU2001255168A1 (en) | 2001-09-17 |
Family
ID=27485932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001255168A Abandoned AU2001255168A1 (en) | 2000-03-03 | 2001-03-01 | Compositions and methods for the treatment of immune related diseases |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2001255168A1 (en) |
| WO (1) | WO2001066740A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094570B2 (en) | 2003-03-11 | 2006-08-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof |
| US7268223B2 (en) | 2000-09-22 | 2007-09-11 | Wyeth | Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof |
| EP1191035A3 (en) * | 2000-09-25 | 2002-04-17 | Schering Aktiengesellschaft | Three members of the cytokin-receptor class II family |
| MXPA03006218A (en) | 2001-01-12 | 2004-09-13 | Inst Genetics Llc | Type 2 ctokine receptor and nucleic acids encoding same. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5383498A (en) * | 1996-12-05 | 1998-06-29 | Human Genome Sciences, Inc. | Human chemokine beta-13 |
| WO2000012708A2 (en) * | 1998-09-01 | 2000-03-09 | Genentech, Inc. | Further pro polypeptides and sequences thereof |
| WO2000078961A1 (en) * | 1999-06-23 | 2000-12-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO1998045437A2 (en) * | 1997-04-10 | 1998-10-15 | Genetics Institute, Inc. | SECRETED EXPRESSED SEQUENCE TAGS (sESTs) |
| WO1999006548A2 (en) * | 1997-08-01 | 1999-02-11 | Genset | 5'ESTs FOR NON TISSUE SPECIFIC SECRETED PROTEINS |
| WO1999025825A2 (en) * | 1997-11-13 | 1999-05-27 | Genset | EXTENDED cDNAs FOR SECRETED PROTEINS |
| EP1053319A2 (en) * | 1998-01-28 | 2000-11-22 | Chiron Corporation | Human genes and gene expression products ii |
| US20020102604A1 (en) * | 1999-12-08 | 2002-08-01 | Milne Edwards Jean-Baptiste Dumas | Full-length human cDNAs encoding potentially secreted proteins |
| CA2343696A1 (en) * | 1998-09-25 | 2000-04-06 | Incyte Pharmaceuticals, Inc. | Membrane-associated organizational proteins |
| CA2373915A1 (en) * | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| EP1067182A3 (en) * | 1999-07-08 | 2001-11-21 | Helix Research Institute | Secretory protein or membrane protein |
| JP3951035B2 (en) * | 1999-09-01 | 2007-08-01 | ジェネンテック・インコーポレーテッド | Secreted and transmembrane polypeptides and nucleic acids encoding them |
| EP2228446A1 (en) * | 1999-12-01 | 2010-09-15 | Genentech, Inc. | Secreted and transmembrane polypeptieds and nucleic acids encoding the same |
-
2001
- 2001-03-01 WO PCT/US2001/006666 patent/WO2001066740A2/en not_active Ceased
- 2001-03-01 AU AU2001255168A patent/AU2001255168A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001066740A3 (en) | 2002-09-19 |
| WO2001066740A2 (en) | 2001-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003072035A8 (en) | Compositions and methods for the treatment of immune related diseases | |
| WO2004041170A9 (en) | Compositions and methods for the treatment of immune related diseases | |
| WO2004024097A9 (en) | Compositions and methods for the treatment of immune related diseases | |
| EP1572116A4 (en) | Compositions and methods for the treatment of immune related diseases | |
| EP1576137A4 (en) | Compositions and methods for the treatment of immune related diseases | |
| AU2002324914A1 (en) | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith | |
| IL145470A0 (en) | Compositions for the treatment of immune diseases | |
| AU7722600A (en) | Compositions and methods for the diagnosis and treatment of immune disorders | |
| AU6147401A (en) | Compositions and methods for the treatment of cancer | |
| AU2495200A (en) | Compositions and methods for the treatment of tumor | |
| AU2003200740A1 (en) | Compositions and methods for the treatment of tumor | |
| AU2003200731A1 (en) | Compositions and methods for the treatment of tumor | |
| AU2003200722A1 (en) | Compositions and methods for the treatment of tumor | |
| EP1560593A4 (en) | Novel composition and methods for the treatment of immune related diseases | |
| AU2002352533A1 (en) | Methods and compositions for treatment of gastric diseases | |
| AU3632600A (en) | Compositions and methods for the treatment of immune related diseases | |
| AU5309600A (en) | Compositions and methods for the treatment and diagnosis of immune disorders | |
| HUP0302718A3 (en) | Methods and compositions for the treatment of diseases of the eye | |
| EP1578373A4 (en) | Novel compositions and methods for the treatment of immune related diseases | |
| AU9395998A (en) | Compositions and methods for the treatment of immune related diseases | |
| IL155174A0 (en) | Methods and compositions for the treatment of inflammatory diseases | |
| AU3434601A (en) | Compositions and methods for the treatment of immune related diseases | |
| WO2004024076A8 (en) | Novel compositions and methods for the treatment of immune related diseases | |
| EP1472273A4 (en) | Compositions and methods for the treatment of immune related diseases | |
| AU2001255730A1 (en) | Methods and compositions for the treatment of cardiac indications |